Ara 290 vs Tesamorelin
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 55% Ara 290 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ara 290 Tesamorelin
Weight 1,257 Da 5,135.9 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) 26-38 minutes
Chain 11 amino acids 44 amino acids
Type Engineered peptide GHRH analog
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Ara 290 Tesamorelin
Status Extensively Studied FDA Approved
References 5 studies 5 studies
Latest 2024 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.